Latest news with #Parkinson
Business Insider
an hour ago
- Business
- Business Insider
Gain Therapeutics announces common stock, warrants offering
Gain Therapeutics (GANX) announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock and warrants to purchase common stock in an underwritten public offering. All of the securities are being offered by the company. Gain intends to use the net proceeds from the offering to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases, including GBA1 Parkinson's disease, and for general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Newbridge Securities Corporation is acting as the sole book-running manager for the proposed offering. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week.
Cision Canada
2 hours ago
- Health
- Cision Canada
Fujitsu and Acer Medical trial AI service that assesses future disease risk in elderly patients through gait pattern abnormality detection
TOKYO, July 15, 2025 /CNW/ -- Fujitsu Limited and Acer Medical Inc., a provider of AI-powered medical imaging and preventative medicine, today announced a collaborative agreement to develop "aiGait" powered by Uvance, a solution that leverages Fujitsu's advanced skeleton recognition AI technology to detect gait pattern abnormalities, and provide gait quantization to healthcare professionals to support the early diagnosis of dementia and Parkinson's disease. The technology is part of "Fujitsu Kozuchi for Vision" from the Fujitsu Uvance offering "AI Technologies and Solutions." The agreement, signed on June 25, 2025, has planned with initial testing at the daycare center attached to the Taipei Veterans Hospital. The testing will utilize cameras to capture data on patient movements, including standing up, sitting down, and walking, and will compare it with movements specific to dementia patients using skeleton recognition AI technology. The solution is expected to be introduced by Acer Medical to elderly care facilities across Taiwan by the end of 2025. By integrating Fujitsu's advanced skeleton recognition AI into its mobile-friendly solution, Acer Medical is transforming routine movements—like standing, sitting, and walking—into valuable clinical insights. The goal of Acer Medical is to help caregivers and clinicians detect subtle changes early, enabling timely intervention and improving patient outcomes. This initiative reflects Acer Medical's broader mission: to bring intelligent, affordable healthcare solutions to communities that need them most. Under the business model Fujitsu Uvance, Fujitsu is building an ecosystem of Uvance Partners that will apply data and AI towards the resolution of social issues. Through co-creation with these partners, and utilizing AI Decision Intelligence, Fujitsu aims to realize high-end health management services and advance people's wellbeing. Under this partnership, Fujitsu and Acer Medical will accelerate efforts to address the social challenges related to gait abnormalities, including their presentation as the early symptoms of dementia and Parkinson's disease. The two companies aim to improve access to elderly care by rolling out this jointly-developed solution to care facilities and primary care clinics in Taiwan and hope to eventually apply it in sports science analysis, pediatric neurodevelopmental disorders, and cerebral palsy.
Local France
8 hours ago
- Health
- Local France
French Expression of the Day: Affection longue durée
Why do I need to know affection longue durée? Well, you don't want to get the wrong end of the stick if your GP mentions it. What does it mean? Affection longue durée – pronounced affec-syon long dyour-ray - might sound like it's a long-lasting friendship or a romantic entanglement that goes on for a long time. But in fact in French affection is a tricky word - it can be used in the same way as in English to mean feeling warm, friendly or loving towards a person. Un sentiment d'affection or un sens d'affection would describe the feeling. But une affection means an ailment or a medical condition. Advertisement On its own its not very commonly used - une maladie or un malaise would be more common for talking about medical conditions in daily life. But the phrase affection longue durée - literally translating as a long-lasting illness - has a very specific meaning. Often referred to by the initialisation ALD, it is the umbrella term for a range of long-term or chronic conditions that require prolonged treatment - ranging from diabetes and asthma to stroke and heart disease, taking in illnesses such as Parkinson's or Alzheimer's, and paraplegia. It also takes in infertility treatments for women, celiac disease and help for deaf children. The definition is important because a nyone with a recognised ALD may be entitled to up to 100 percent of the cost of related care covered by the healthcare system. In fact, there's a list – known as the ALD 30 – of conditions that qualify for this level of reimbursement. It's a non-exhaustive list, as today additional conditions are recognised as requiring care lasting more than six months. Having an ALD may also entitle you to certain benefits or financial aid, so if you have an illness that you think qualifies you, it's well worth talking to your doctor about getting the official ALD designation. Use it like this Pour faire reconnaître une maladie comme affection de longue durée, vous devez consulter votre médecin traitant – To have a condition recognised as a long-term illness, you must consult your GP.
Leader Live
12 hours ago
- Health
- Leader Live
Weight loss jab Mounjaro linked to lower dementia risk
Academics said the benefits of drugs such as Wegovy and Mounjaro – including for managing weight and blood sugar levels – are well known, but other health benefits of the popular drugs remain 'unclear'. People with type 2 diabetes and obesity who are taking the drugs are also less likely to die prematurely, researchers found. The study saw experts from Taiwan examine date on 60,000 people from around the world, with an average age of 58, who had type 2 diabetes and obesity. Key differences between three weight-loss injections: Mounjaro, Wegovy, and Ozempic. Around half were given GLP agonist drugs semaglutide and tirzepatide – which are sold under the brand names Wegovy and Mounjaro. Semaglutide is also the main ingredient for the type 2 diabetes drug Ozempic. GLP agonists can reduce a person's appetite; slow down their digestion; reduce the amount of sugar the liver makes and they help the body to make more insulin when needed. The other half used other anti-diabetic medication. 📢Important update Eligible people in #Dorset will be able to access Tirzepatide (Mounjaro) weight management medication from autumn 2025. ✅Around 1,000 people in Dorset will qualify under strict national criteria ✅No need to contact your doctor More: During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37% lower risk of dementia and a 19% reduced risk of stroke. They were also 30% less likely to die during the follow-up period. And when researchers looked at the data further they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. Recommended reading: 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.' Recommended reading: Dr Richard Oakley, associate director of research and innovation at Alzheimer's Society, said: 'It is well established that diabetes and obesity can increase your risk of developing dementia. 'This study supports existing evidence that shows these drugs may reduce dementia risk, particularly for people aged 60 and over who are living with type 2 diabetes and obesity. 'Although interesting, we can't draw conclusions from this study alone as it is an observational study, only a small number of people who took part went on to develop dementia and as the impact of these drugs on different types of dementia is not clear. 'There are clinical trials currently looking at whether drugs like these can be used to treat early-stage Alzheimer's disease, so this is a really exciting area being explored in the research fight against dementia.'
Yahoo
12 hours ago
- Health
- Yahoo
Hidden health benefits from weight-loss shots revealed
Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious conditions such as dementia and stroke, a new study has indicated. The research also suggests that individuals with type 2 diabetes and obesity who are prescribed these medications could face a reduced risk of premature death. Academics behind the study noted that while the efficacy of GLP agonist drugs – such as semaglutide (found in Wegovy and Ozempic) and tirzepatide (Mounjaro) – in managing weight and blood sugar levels is widely recognised, their wider health benefits have remained less understood. The comprehensive study, conducted by experts in Taiwan, examined data from 60,000 people worldwide, with an average age of 58, all diagnosed with type 2 diabetes and obesity. Roughly half of the participants were given GLP agonist drugs. These medications function by curbing appetite, slowing digestion, reducing the liver's sugar output, and enhancing the body's insulin production when required. The other half used other anti-diabetic medication. During a seven-year follow-up period, researchers found that people given the GLP agonist drugs appeared to have a 37 per cent lower risk of dementia and a 19 per cent reduced risk of stroke. Weight-loss drugs like Wegovy are available on the NHS to obese patients They were also 30 per cent less likely to die during the follow-up period. When researchers looked at the data further, they found even greater benefits in people aged 60 or older, women, and those with a body mass index score of 30 to 40. They found no differences in Parkinson's disease or brain bleeds. The academics said their findings suggest 'potential neuroprotective and cerebrovascular benefits' of the drugs but they called for more studies to confirm the findings. 'These findings suggest that semaglutide and tirzepatide may offer neuroprotective and cerebrovascular benefits beyond glycemic control, potentially improving long-term cognitive and survival outcomes in adults with type 2 diabetes and obesity,' they wrote in the journal JAMA Network Open. Commenting on the study, Professor Tara Spires-Jones, director of the Centre for Discovery Brain Sciences at the University of Edinburgh and group leader in the UK Dementia Research Institute, said: 'This is a very interesting study adding to evidence that GLP1 receptor agonists are associated with a lower risk of dementia in people with type 2 diabetes and obesity. 'This type of study cannot determine whether the drugs reduced disease risk by directly protecting the brain. 'It is highly likely that effectively treating type 2 diabetes and obesity would reduce dementia and stroke risk as they are known risk factors for these conditions. 'Further work is needed including randomised clinical trials to confirm these drugs are protective in people with diabetes and obesity and other trials are needed to determine whether these drugs will be protective in people who do not have type 2 diabetes and obesity.'
